Microstructural characterization of Mg-SiC nanocomposite synthesized by high energy ball milling

High-energy ball milling is successfully used to produce magnesium matrix nanocomposites reinforced with SiC nanoparticles. Changes in morphology and microstructural features of the milled powders were characterized in order to highlight advantages of the mechanical milling process and evaluate the role of the SiC nanoparticles. It was observed that with increasing volume fraction of SiC nanoparticles, a finer nanocomposite powder with more uniform particle size distribution is obtained. A homogeneous distribution of SiC nanoparticles, even up to 10% volume fraction, in magnesium matrix after 25 h milling was confirmed by elemental mapping and TEM results. The analysis of the XRD patterns accompanied by dark-field TEM images revealed that magnesium crystallites refine to fine nanocrystalline sizes after the mechanical milling. The results showed that the crystallite size of the magnesium matrix reduced with increasing SiC nanoparticle content in addition to the induced lattice strain

Successive occurrence of 2 Genetically distinct Burkitt lymphomas: pathophysiological significance and clinical consequences

Nous rapportons le cas exceptionnel d’un patient âgé de 25 ans qui a développé, en moins de 2 ans, 2 lymphomes de Burkitt (LB). La cytogénétique et les techniques de biologie moléculaire ont montré que les 2 LB étaient issus de 2 clones distincts

Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11)

BCR-ABL1 negative myeloproliferative neoplasms (MPNs) are known to contain alterations of the tyrosine kinase JAK2 (located on 9p24) that result in constitutive activation of the encoded protein. JAK2 fusions are reported in acute and chronic leukemias of myeloid and lymphoid phenotypes. Here, we report an unclassified case of MPN (MPN-U) showing a t(9;22)(p24;q11), which generates a BCR-JAK2 fusion gene by fusing the BCR at intron 13 to JAK2 at intron 17 on the derivative chromosome 22. Most reported JAK2 fusions cases reveal an aggressive clinical course and long-term remissions have only been achieved after allogeneic stem cell transplantation (ASCT). To the best of our knowledge, this is the thirteenth case reported worldwide to describe a BCR-JAK2 fusion transcript in MPN-U. The present report revealed a sustained complete clinical, hematologic, and cytogenetic remission 35 months after diagnosis and ~24 months after ASCT. Regarding BCR-ABL1  negative MPN patients this case report provides strong support for a role of JAK2 activation in the oncogenesis and suggests a possible diagnostic and therapeutic target that should be investigated